Gemigliptin is prescribed to patients suffering from type 2 diabetes to control blood glucose levels. It helps in reducing blood glucose levels by stimulating insulin release from pancreas and increasing sensitivity of body cells to insulin. The growing geriatric population is more prone to develop type 2 diabetes due to age-related changes in body metabolism, thereby increasing demand for antidiabetic drugs like Gemigliptin.

The global Gemigliptin Market is estimated to be valued at US$ 1.79 Bn in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Increasing geriatric population: The risk of developing type 2 diabetes increases with age. As per World Health Organization (WHO) projections, the global geriatric population aged 60 years and above is expected to double from 12% to 22% between 2015 and 2050. Growing diabetic patient pool with age propels demand for antidiabetic drugs like Gemigliptin to manage blood glucose levels in older population over 65 years of age.

SWOT Analysis

Strength: Gemigliptin is a newer drug with fewer side effects compared to other alternatives. It provides effective glycemic control for type 2 diabetes patients.
Weakness: Being a relatively new drug, brand recognition and doctor prescription rates for Gemigliptin are still low compared to older drugs.
Opportunity: Increasing diabetes prevalence worldwide offers potential for market growth. Growth opportunities exist in expanding to new geographies and indication areas.
Threats: Intense competition from cheaper generic versions and other branded drugs poses pricing and market share threats. Stringent regulations around clinical trials and approvals are a challenge.

Key Takeaways

The Global Gemigliptin Market Share is expected to witness high growth. The global Gemigliptin Market is estimated to be valued at US$ 1.79 Bn in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030.

Regional analysis comprises the Asia Pacific region currently dominates the market and is expected to be the fastest growing as well as most lucrative region over the forecast period. Several factors such as rising geriatric population, growing obesity, sedentary lifestyle are contributing to the increasing prevalence of type 2 diabetes in the region.

Key players operating in the gemigliptin market are Samsung, Apple Inc., Microsoft Corporation, Mozo Accessories, iLuv Creative Technology, Energizer, Case-mate. Gemigliptin was developed by LG Life Sciences and received regulatory approval in South Korea in 2013. The drug is now also sold in other Asian markets through generic manufacturers and private label distributors.

Key players like Samsung and Apple focus on strengthening their digital pharmaceutical offering

Gemigliptin is prescribed to patients suffering from type 2 diabetes to control blood glucose levels. It helps in reducing blood glucose levels by stimulating insulin release from pancreas and increasing sensitivity of body cells to insulin. The growing geriatric population is more prone to develop type 2 diabetes due to age-related changes in body metabolism, thereby increasing demand for antidiabetic drugs like Gemigliptin.

The global Gemigliptin Market is estimated to be valued at US$ 1.79 Bn in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
Increasing geriatric population: The risk of developing type 2 diabetes increases with age. As per World Health Organization (WHO) projections, the global geriatric population aged 60 years and above is expected to double from 12% to 22% between 2015 and 2050. Growing diabetic patient pool with age propels demand for antidiabetic drugs like Gemigliptin to manage blood glucose levels in older population over 65 years of age.

SWOT Analysis

Strength: Gemigliptin is a newer drug with fewer side effects compared to other alternatives. It provides effective glycemic control for type 2 diabetes patients.
Weakness: Being a relatively new drug, brand recognition and doctor prescription rates for Gemigliptin are still low compared to older drugs.
Opportunity: Increasing diabetes prevalence worldwide offers potential for market growth. Growth opportunities exist in expanding to new geographies and indication areas.
Threats: Intense competition from cheaper generic versions and other branded drugs poses pricing and market share threats. Stringent regulations around clinical trials and approvals are a challenge.

Key Takeaways

The Global Gemigliptin Market Share is expected to witness high growth. The global Gemigliptin Market is estimated to be valued at US$ 1.79 Bn in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030.

Regional analysis comprises the Asia Pacific region currently dominates the market and is expected to be the fastest growing as well as most lucrative region over the forecast period. Several factors such as rising geriatric population, growing obesity, sedentary lifestyle are contributing to the increasing prevalence of type 2 diabetes in the region.

Key players operating in the gemigliptin market are Samsung, Apple Inc., Microsoft Corporation, Mozo Accessories, iLuv Creative Technology, Energizer, Case-mate. Gemigliptin was developed by LG Life Sciences and received regulatory approval in South Korea in 2013. The drug is now also sold in other Asian markets through generic manufacturers and private label distributors.

Key players like Samsung and Apple focus on strengthening their digital pharmaceutical offerings and solutions around diabetes management. Partnerships with pharma companies and healthcare providers help improve medication adherence and monitoring. Players also explore new geographical markets and access payer channels to drive prescription volumes and market share.

For more details on the report, Read- https://www.pressreleasebulletin.com/gemigliptin-market-trends-size-and-share-analysis/

s and solutions around diabetes management. Partnerships with pharma companies and healthcare providers help improve medication adherence and monitoring. Players also explore new geographical markets and access payer channels to drive prescription volumes and market share.

For more details on the report, Read- https://www.pressreleasebulletin.com/gemigliptin-market-trends-size-and-share-analysis/